Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells

Chimeric antigen receptor (CAR) T cell therapy is an FDA-approved treatment for several hematologic malignancies, yet not all patients respond to this treatment. While some resistance mechanisms have been identified, cell death pathways in target cancer cells remain underexplored. Impairing mitochon...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourzia, Alexandra L., Olson, Michael L., Bailey, Stefanie R., Boroughs, Angela C., Aryal, Aditi, Ryan, Jeremy, Maus, Marcela V., Letai, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101951/
https://www.ncbi.nlm.nih.gov/pubmed/37055388
http://dx.doi.org/10.1038/s41419-023-05727-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101951/
https://www.ncbi.nlm.nih.gov/pubmed/37055388
http://dx.doi.org/10.1038/s41419-023-05727-x

Ejemplares similares